基于蒽环类药物的外周T细胞淋巴瘤前线化疗方案的系统回顾和元分析》（A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma）。
Abeer N Abouyabis, Pareen J Shenoy, Rajni Sinha, Christopher R Flowers, Mary Jo Lechowicz
{"title":"基于蒽环类药物的外周T细胞淋巴瘤前线化疗方案的系统回顾和元分析》（A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma）。","authors":"Abeer N Abouyabis, Pareen J Shenoy, Rajni Sinha, Christopher R Flowers, Mary Jo Lechowicz","doi":"10.5402/2011/623924","DOIUrl":null,"url":null,"abstract":"<p><p>Anthracycline-based chemotherapy remains standard treatment for peripheral T-cell lymphoma (PTCL) although its benefits have been questioned. We performed systematic literature review and meta-analyses examining the complete response (CR) and overall survival (OS) rates for patients with PTCL. The CR rate for PTCL patients ranged from 35.9% (95% CI 23.4-50.7%) for enteropathy-type T-cell lymphoma (ETTL) to 65.8% (95% CI 54.0-75.9%) for anaplastic large cell lymphoma (ALCL). The 5-year OS was 38.5% (95% CI 35.5-41.6%) for all PTCL patients and ranged from 20.3% (95% CI 12.5-31.2%) for ETTL to 56.5% (95% CI 42.8-69.2%) for ALCL. These data suggest that there is marked heterogeneity across PTCL subtypes in the benefits of anthracycline-based chemotherapy. While anthracyclines produce CR in half of PTCL patients, this yields reasonable 5-year OS for patients with ALCL but not for those with PTCL-NOS or ETTL. Novel agents and regimens are needed to improve outcomes for these patients.</p>","PeriodicalId":14727,"journal":{"name":"ISRN Hematology","volume":"2011 ","pages":"623924"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197255/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma.\",\"authors\":\"Abeer N Abouyabis, Pareen J Shenoy, Rajni Sinha, Christopher R Flowers, Mary Jo Lechowicz\",\"doi\":\"10.5402/2011/623924\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Anthracycline-based chemotherapy remains standard treatment for peripheral T-cell lymphoma (PTCL) although its benefits have been questioned. We performed systematic literature review and meta-analyses examining the complete response (CR) and overall survival (OS) rates for patients with PTCL. The CR rate for PTCL patients ranged from 35.9% (95% CI 23.4-50.7%) for enteropathy-type T-cell lymphoma (ETTL) to 65.8% (95% CI 54.0-75.9%) for anaplastic large cell lymphoma (ALCL). The 5-year OS was 38.5% (95% CI 35.5-41.6%) for all PTCL patients and ranged from 20.3% (95% CI 12.5-31.2%) for ETTL to 56.5% (95% CI 42.8-69.2%) for ALCL. These data suggest that there is marked heterogeneity across PTCL subtypes in the benefits of anthracycline-based chemotherapy. While anthracyclines produce CR in half of PTCL patients, this yields reasonable 5-year OS for patients with ALCL but not for those with PTCL-NOS or ETTL. Novel agents and regimens are needed to improve outcomes for these patients.</p>\",\"PeriodicalId\":14727,\"journal\":{\"name\":\"ISRN Hematology\",\"volume\":\"2011 \",\"pages\":\"623924\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197255/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ISRN Hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5402/2011/623924\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2011/6/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ISRN Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5402/2011/623924","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2011/6/16 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
以蒽环类药物为基础的化疗仍然是外周T细胞淋巴瘤（PTCL）的标准治疗方法，尽管其疗效受到质疑。我们对 PTCL 患者的完全缓解率（CR）和总生存率（OS）进行了系统的文献综述和荟萃分析。PTCL患者的CR率从肠病型T细胞淋巴瘤（ETTL）的35.9%（95% CI 23.4-50.7%）到无细胞大细胞淋巴瘤（ALCL）的65.8%（95% CI 54.0-75.9%）不等。所有PTCL患者的5年OS为38.5%（95% CI 35.5-41.6%），ETTL为20.3%（95% CI 12.5-31.2%），ALCL为56.5%（95% CI 42.8-69.2%）。这些数据表明，不同亚型的PTCL在蒽环类化疗的获益方面存在明显的异质性。虽然蒽环类药物可使半数 PTCL 患者达到 CR，但 ALCLL 患者可获得合理的 5 年 OS，而 PTCL-NOS 或 ETTL 患者则不能。我们需要新的药物和方案来改善这些患者的预后。
A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma.
Anthracycline-based chemotherapy remains standard treatment for peripheral T-cell lymphoma (PTCL) although its benefits have been questioned. We performed systematic literature review and meta-analyses examining the complete response (CR) and overall survival (OS) rates for patients with PTCL. The CR rate for PTCL patients ranged from 35.9% (95% CI 23.4-50.7%) for enteropathy-type T-cell lymphoma (ETTL) to 65.8% (95% CI 54.0-75.9%) for anaplastic large cell lymphoma (ALCL). The 5-year OS was 38.5% (95% CI 35.5-41.6%) for all PTCL patients and ranged from 20.3% (95% CI 12.5-31.2%) for ETTL to 56.5% (95% CI 42.8-69.2%) for ALCL. These data suggest that there is marked heterogeneity across PTCL subtypes in the benefits of anthracycline-based chemotherapy. While anthracyclines produce CR in half of PTCL patients, this yields reasonable 5-year OS for patients with ALCL but not for those with PTCL-NOS or ETTL. Novel agents and regimens are needed to improve outcomes for these patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
